Consistent Revenue Growth: Teva Pharmaceutical reported Q2 2025 revenues of $4.2 billion, reflecting a 1% growth year-over-year (YOY). This marks the company¡¯s 10th consecutive quarter of growth, primarily driven by its innovative portfolio, including AUSTEDO (up 19% to nearly $500 million), UZEDY (up 120% to $54 million), and AJOVY (up 31% to $155 million). Adjusted EBITDA grew by 7% and non-GAAP EPS increased by 10% to $0.66.

Innovative Pipeline and Future Projections: The company expressed confidence in its growth trajectory, with a projected growth of its innovative portfolio to achieve $3.5 billion to $4 billion by 2027. Key upcoming milestones include the expected 2024 launch of the long-acting olanzapine and the promising performance of the DARI dual-action asthma inhaler and duvakitug candidates.

Challenges in Generics Business: Teva's global generics business saw a decline of 2% YOY, attributed to tough prior year comparisons and a decline in TAPI revenues (down 11%), which is expected to be temporary due to seasonal factors. The company maintained guidance for flat to low single-digit growth in the generics segment for 2025.